---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-142297"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:15:55.121681+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cerus Q1 total revenue $43.0M (+46% YoY); raises FY product revenue guidance to $160-165M

## Summary
- Product revenue $37.4M (+60% YoY) driven by INTERCEPT platelet kit sales in the U.S.
- Net loss improved to $12.3M ($0.07/shr) vs $17.5M ($0.10/shr) a year ago.
- Non-GAAP Adjusted EBITDA improved to -$3.7M from -$11.5M year-over-year.
- Signed multi-year INTERCEPT platelet contract with American Red Cross and 10-year Fresenius Kabi manufacturing extension.
- Cash and investments $108.6M at March 31, 2022; net cash used in operations $21.5M.

## SEC filing metadata
- accession: 0001193125-22-142297
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000119312522142297/0001193125-22-142297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000119312522142297/d667280d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-142297
- JSON: https://secwatch.observer/filing/0001193125-22-142297.json
- Plain text: https://secwatch.observer/filing/0001193125-22-142297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.